Evaluate gives you the understanding and time you need to drive better decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

How we can help you
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Market Reports
Market Reports
Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview. 

More
EvaluatePharma
OUR PRODUCTS
EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the first single view of the risk and reward of the R&D landscape from EvaluatePharma Vision.

More
custom solutions
OUR SERVICES
Custom Solutions

Improve your strategic decision-making with customised solutions that draw on our team of industry experts and trusted commercial intelligence. 

More
Kickstarting ideas
 Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Thumbnail

Biogen’s aducanumab shoulders sector’s pipeline hopes, again

Celgene's CAR-T and Glaxosmithkline's antibody-drug conjugate are among the industry's most valuable R&D assets.
Thumbnail

US agency to rule on Tecentriq’s most important use

Roche will find out by September 5 whether its shot at a first-line US lung cancer label has hit the mark.
Thumbnail

Most valuable unpartnered assets reveal a changing of the guard

Thumbnail

Deepmind’s AI works, but making money remains elusive

Thumbnail

Amryt awaits crucial readout as it prepares rare disease push

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up